|
1
|
Morphine and alternative opioids in cancer pain: the EAPC recommendations.
|
Br J Cancer
|
2001
|
3.40
|
|
2
|
Quality-of-life assessment during a palliative care programme.
|
Ann Oncol
|
1990
|
2.67
|
|
3
|
Strategies to manage the adverse effects of oral morphine: an evidence-based report.
|
J Clin Oncol
|
2001
|
2.25
|
|
4
|
Symptom prevalence and control during cancer patients' last days of life.
|
J Palliat Care
|
1990
|
2.22
|
|
5
|
Subcutaneous morphine for dyspnea in cancer patients.
|
Ann Intern Med
|
1993
|
1.95
|
|
6
|
Morphine for relief of cancer pain.
|
Lancet
|
1996
|
1.47
|
|
7
|
Proximal femur geometry to detect and distinguish femoral neck fractures from trochanteric fractures in postmenopausal women.
|
Osteoporos Int
|
2002
|
1.37
|
|
8
|
The use of bone-graft substitutes in large bone defects: any specific needs?
|
Injury
|
2011
|
1.35
|
|
9
|
WHO guidelines for the use of analgesics in cancer pain.
|
Int J Tissue React
|
1985
|
1.18
|
|
10
|
Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study.
|
J Clin Oncol
|
2001
|
1.17
|
|
11
|
Geometry of proximal femur in the prediction of hip fracture in osteoporotic women.
|
Br J Radiol
|
1999
|
1.16
|
|
12
|
The management of constipation in palliative care: clinical practice recommendations.
|
Palliat Med
|
2008
|
1.09
|
|
13
|
Prevalence, distress, management, and relief of pain during the last 3 months of cancer patients' life. Results of an Italian mortality follow-back survey.
|
Ann Oncol
|
2009
|
1.09
|
|
14
|
Characteristics of terminal cancer patients who committed suicide during a home palliative care program.
|
J Pain Symptom Manage
|
2001
|
1.06
|
|
15
|
Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients.
|
J Clin Oncol
|
1996
|
1.04
|
|
16
|
The effects of methotrexate (MTX) on bone. A densitometric study conducted on 59 patients with MTX administered at different doses.
|
Ital J Orthop Traumatol
|
1988
|
1.02
|
|
17
|
Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction.
|
Support Care Cancer
|
2000
|
1.00
|
|
18
|
Antidepressants increase bioavailability of morphine in cancer patients.
|
Lancet
|
1987
|
0.98
|
|
19
|
The management of inoperable gastrointestinal obstruction in terminal cancer patients.
|
Tumori
|
1990
|
0.94
|
|
20
|
The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials.
|
Pain
|
1998
|
0.94
|
|
21
|
Invariant cone-excitation ratios may predict transparency.
|
J Opt Soc Am A Opt Image Sci Vis
|
2000
|
0.92
|
|
22
|
Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain.
|
J Clin Oncol
|
1995
|
0.91
|
|
23
|
Prescription of opioids in Italy: everything, but the morphine.
|
Ann Oncol
|
2009
|
0.90
|
|
24
|
Suicide among patients with cancer cared for at home by palliative-care teams.
|
Lancet
|
1999
|
0.89
|
|
25
|
A randomized study on oral administration of morphine and methadone in the treatment of cancer pain.
|
J Pain Symptom Manage
|
1986
|
0.89
|
|
26
|
Oral complications in patients with advanced cancer.
|
J Palliat Care
|
1989
|
0.89
|
|
27
|
Comparison of home and hospital care of advanced cancer patients.
|
Tumori
|
1989
|
0.88
|
|
28
|
Propofol in terminal care.
|
J Pain Symptom Manage
|
1995
|
0.87
|
|
29
|
Subcutaneous octreotide in the treatment of pain in advanced cancer patients.
|
J Pain Symptom Manage
|
1994
|
0.86
|
|
30
|
Bone mineral density and bone loss measured at the radius to predict the risk of nonspinal osteoporotic fracture.
|
J Bone Miner Res
|
2001
|
0.85
|
|
31
|
Diclofenac does not modify morphine bioavailability in cancer patients.
|
Pain
|
1992
|
0.84
|
|
32
|
Discriminant capacity of quantitative ultrasound versus dual X-ray absorptiometry to determine cancellous bone loss in ovariectomized rats.
|
Bone
|
2000
|
0.84
|
|
33
|
Treatment of long bone non-unions with polytherapy: indications and clinical results.
|
Injury
|
2011
|
0.84
|
|
34
|
Studies on the effects of antidepressant drugs on the antinociceptive action of morphine and on plasma morphine in rat and man.
|
Pain
|
1990
|
0.84
|
|
35
|
Side effects of morphine administration in cancer patients.
|
Cancer Nurs
|
1998
|
0.82
|
|
36
|
Tolerability of ketorolac administered via continuous subcutaneous infusion for cancer pain: a preliminary report.
|
J Pain Symptom Manage
|
1994
|
0.82
|
|
37
|
Calcitriol and alendronate combination treatment in menopausal women with low bone mass.
|
Int J Tissue React
|
1999
|
0.81
|
|
38
|
Polytherapy in bone regeneration: clinical applications and preliminary considerations.
|
Int J Immunopathol Pharmacol
|
2011
|
0.77
|
|
39
|
The role of disodium pamidronate in the management of bone pain due to malignancy.
|
Palliat Med
|
2001
|
0.77
|
|
40
|
Evaluation of an experimental model of osteoporosis induced in the female rat through ovariectomy.
|
Boll Soc Ital Biol Sper
|
1994
|
0.77
|
|
41
|
Plasma morphine and morphine-6-glucuronide patterns in cancer patients after oral, subcutaneous, sublabial and rectal short-term administration.
|
Int J Clin Pharmacol Res
|
1991
|
0.77
|
|
42
|
Monotherapy vs. polytherapy in the treatment of forearm non-unions and bone defects.
|
Injury
|
2013
|
0.77
|
|
43
|
Antidepressants in cancer pain.
|
J Palliat Care
|
1991
|
0.77
|
|
44
|
Short-term effects of pamidronate on bone turnover: can bone markers be considered predictive of the analgesic response?
|
Oncol Rep
|
2007
|
0.77
|
|
45
|
A randomized double-blind crossover trial of intravenous lidocaine in the treatment of neuropathic cancer pain.
|
J Pain Symptom Manage
|
1992
|
0.77
|
|
46
|
Rapid discontinuation of hypnotics in terminal cancer patients: a prospective study.
|
Ann Oncol
|
1996
|
0.77
|
|
47
|
A clinical study on the use of codeine, oxycodone, dextropropoxyphene, buprenorphine, and pentazocine in cancer pain.
|
J Pain Symptom Manage
|
1991
|
0.76
|
|
48
|
The MERITO Study: a multicentre trial of the analgesic effect and tolerability of normal-release oral morphine during 'titration phase' in patients with cancer pain.
|
Palliat Med
|
2008
|
0.76
|
|
49
|
Can somatostatin be administered in association with morphine in advanced cancer patients with pain?
|
Ann Oncol
|
1998
|
0.76
|
|
50
|
Taste alterations in cancer patients.
|
J Pain Symptom Manage
|
1998
|
0.76
|
|
51
|
Quantitative ultrasound and bone densitometry to evaluate the risk of nonspine fractures: a prospective study.
|
Osteoporos Int
|
2000
|
0.75
|
|
52
|
Ultrasound in the evaluation of osteoporosis: a comparison with bone mineral density at distal radius.
|
Br J Radiol
|
1995
|
0.75
|
|
53
|
Leucocyte-lymphocyte ratio as prognostic indicator of survival in cachectic cancer patients.
|
Ann Oncol
|
1991
|
0.75
|
|
54
|
Serum levels of tartrate-resistant acid phosphatase-5b in breast cancer patients treated with pamidronate.
|
Int J Biol Markers
|
2003
|
0.75
|
|
55
|
Frequency of suicide by cancer patients at the National Cancer Institute of Milan over 1986-90.
|
Ann Oncol
|
1991
|
0.75
|
|
56
|
Rectal opioid medications: our experiences.
|
J Pain Symptom Manage
|
1997
|
0.75
|
|
57
|
Palliative care at the National Cancer Institute of Milan.
|
Support Care Cancer
|
2001
|
0.75
|
|
58
|
[Controlled clinical trial of a new substance with hepatotropic activity, carried out with an experimental cross-over plan in double-blind conditions].
|
Clin Ter
|
1972
|
0.75
|
|
59
|
Pain relief and sclerosis of bone metastases in a patient with breast cancer treated with tamoxifen, radiotherapy and pamidronate disodium: which treatment helped?
|
J Pain Symptom Manage
|
1998
|
0.75
|
|
60
|
The pharmacological management of cancer pain. Part 1: The role of non opioid and adjuvant drugs.
|
Ann Oncol
|
1993
|
0.75
|
|
61
|
Dissociation of the effects of acute chlomipramine on morphine analgesia and plasma concentrations.
|
Arch Int Pharmacodyn Ther
|
1989
|
0.75
|
|
62
|
Carcinoid somatostatinoma of the duodenum.
|
Eur J Surg Oncol
|
1998
|
0.75
|
|
63
|
Unendurable symptoms as prognostic indicators of impending death in terminal cancer patients.
|
Eur J Cancer
|
1990
|
0.75
|
|
64
|
Diclofenac does not modify methadone bioavailability in cancer patients.
|
J Pain Symptom Manage
|
1999
|
0.75
|
|
65
|
[Femoral neck morphology differentiates femoral neck from vertebral or hip osteoporotic fracture].
|
Reumatismo
|
2003
|
0.75
|
|
66
|
Non-steroidal anti-inflammatory drugs as the first step in cancer pain therapy: double-blind, within-patient study comparing nine drugs.
|
J Int Med Res
|
1990
|
0.75
|
|
67
|
The pharmacological management of cancer pain. Part II: The role of opioid drugs in adults and children.
|
Ann Oncol
|
1993
|
0.75
|
|
68
|
The importance of urinary hydroxyproline and serumal osteocalcin in the evaluation of post-menopausal osteoporosis.
|
Ital J Orthop Traumatol
|
1990
|
0.75
|
|
69
|
[Buprenorphine in cancer pain: cross comparison with pentazocine].
|
Minerva Med
|
1987
|
0.75
|
|
70
|
[Acute study of parenteral buprenorphine versus parenteral morphine].
|
Minerva Anestesiol
|
1987
|
0.75
|
|
71
|
On the "last days of life".
|
J Palliat Care
|
1993
|
0.75
|
|
72
|
Italian validation of the Purpose In Life (PIL) test and the Seeking Of Noetic Goals (SONG) test in a population of cancer patients.
|
Support Care Cancer
|
2012
|
0.75
|
|
73
|
Treatment of postoperative pain: comparison between administration at fixed hours and 'on demand' with intramuscular analgesics.
|
Eur J Surg Oncol
|
1989
|
0.75
|
|
74
|
Use of trade names of drugs in abstracts from pain congresses.
|
N Engl J Med
|
2000
|
0.75
|
|
75
|
Loss of bone mass after total hip replacement: preliminary data.
|
Chir Organi Mov
|
1999
|
0.75
|
|
76
|
The mechanical properties of fluoride-treated bone in the ovariectomized rat.
|
Calcif Tissue Int
|
1999
|
0.75
|
|
77
|
Treatment of myeloproliferative syndrome with hydroxyurea.
|
Ann Hematol
|
1996
|
0.75
|
|
78
|
Issues in symptom control. Part 4. Oral complications in patients with advanced cancer.
|
J Pain Symptom Manage
|
1989
|
0.75
|
|
79
|
A clinical note on sublingual buprenorphine.
|
J Palliat Care
|
1993
|
0.75
|